EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial

Luc Biedermann iD, Michael Doulberis iD, Philipp Schreiner, Ole Haagen Nielsen iD, Frans Olivier The, Stephan Brand, Sabine Burk, Petr Hruz, Pascal Juillerat, Claudia Krieger-Grübel iD, Kristin Leu, Gabriel E Leventhal iD und 6 weitere

Nutrients · 2024

DOI: 10.3390/nu16234197 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Luc Biedermann und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Anthocyanins, Plant Extracts. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SNF, Swiss National Science Foundation (SNF), Litwin Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bilberries are effective in inducing clinical, endoscopic, and biochemical improvement in ulcerative colitis (UC) patients. The aim of this study was to investigate the efficacy of anthocyanin-rich extract (ACRE), the bioactive ingredient of bilberries, in a controlled clinical trial in moderate-to-severe UC.

Methods

A multi-center, randomized, placebo-controlled, double-blind study with a parallel group was conducted. Initially, the study was planned for 100 patients; nevertheless, it prematurely ended due to COVID-19. Patients had moderate-to-severe active UC at screening (a Mayo score of 6–12, an endoscopic sub-score ≥ 2) and were randomized at baseline. The primary endpoint was a clinical response (week 8, a total Mayo score reduction ≥ 3 points). Fecal calprotectin (FC) and a centrally read endoscopic response were among the secondary endpoints.

Results

Out of 48 patients (6 Swiss centers), 34 were randomized. Eighteen ACRE and eight placebo patients could be analyzed (per protocol set). Half (9/18) of ACRE patients and 3/8 of placebo patients responded clinically (p = 0.278). An improvement in the Mayo score was observed in the ACRE arm (77.8% vs. 62.5% placebo). FC dropped from 1049 ± 1139 to 557 ± 756 μg/g for ACRE but not for the placebo group (947 ± 1039 to 1040 ± 1179; p = 0.035). Serious adverse events were rare.

Conclusions

ACRE treatment did not yield significant superiority to the placebo. Furthermore, the placebo response was unusually high. Moreover, there was a significant calprotectin decrease at the end of treatment, indicative of ACRE efficacy in UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeAnthocyaninsPlant ExtractsHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultTreatment OutcomeFecesLeukocyte L1 Antigen ComplexVaccinium myrtillusAgedCOVID-19

Stichwörter der Autor:innen

anthocyanin-rich extract (ACRE)bilberriescomplementary therapyinflammatory bowel disease (IBD)ulcerative colitis

Substanzen

AnthocyaninsPlant ExtractsLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
  • Gastroklinik, Private Gastroenterological Practice, 8810 Horgen, Switzerland.
  • Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, 5001 Aarau, Switzerland.
  • Department of Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, 2730 Herlev, Denmark.
  • Department of Gastroenterology and Hepatology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland.
  • Department of Gastroenterology, Clarunis-University Center for Gastrointestinal and Liver Diseases, 4052 Basel, Switzerland.

ORCID-Profile: Luc Biedermann, Michael Doulberis, Ole Haagen Nielsen, Claudia Krieger-Grübel, Gabriel E Leventhal, Sylvie Scharl, Hans Herfarth, Gerhard Rogler

Förderung

  • SNF
  • Swiss National Science Foundation (SNF)
  • Litwin Foundation

Zitieren

APA

Biedermann, L., Doulberis, M., Schreiner, P., Nielsen, O. H., The, F. O., Brand, S., Burk, S., Hruz, P., Juillerat, P., Krieger-Grübel, C., Leu, K., Leventhal, G. E., Misselwitz, B., Scharl, S., Schoepfer, A., Seibold, F., Herfarth, H., & Rogler, G. (2024). Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial. Nutrients. https://doi.org/10.3390/nu16234197

Vancouver

Biedermann L, Doulberis M, Schreiner P, Nielsen OH, The FO, Brand S, et al. Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial. Nutrients. 2024. doi:10.3390/nu16234197

BibTeX
@article{Biedermann2024,
  author = {Biedermann, Luc and Doulberis, Michael and Schreiner, Philipp and Nielsen, Ole Haagen and The, Frans Olivier and Brand, Stephan and Burk, Sabine and Hruz, Petr and Juillerat, Pascal and Krieger-Grübel, Claudia and Leu, Kristin and Leventhal, Gabriel E and Misselwitz, Benjamin and Scharl, Sylvie and Schoepfer, Alain and Seibold, Frank and Herfarth, Hans and Rogler, Gerhard},
  title = {Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16234197}
}
Kostenlos starten →